For the Inventor, By the Inventor

Enter assignee name

Hybrigenics S.a.

USPTO Granted Patents = 10

CIPO Patents = 6

EPO Patents = 7

Trademarks = 4

Forward Citations = 41

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

Rémi Delansorne (5 out of 5 patents)

Frédéric Colland (4 out of 4 patents)

Jean-Christophe Rain (4 out of 12 patents)

4. Philippe Guedat (3 out of 13 patents)

5. Etienne Formstecher (3 out of 3 patents)

6. Xavier Jacq (3 out of 3 patents)

7. Laurent Daviet (3 out of 3 patents)

8. Guillaume Boissy (2 out of 2 patents)

9. Catherine Borg-Capra (2 out of 2 patents)

10. Matteo Colombo (2 out of 2 patents)

11. Susan Benjamin (1 out of 1 patent)

12. Cécile Planquette (1 out of 1 patent)

13. Marie-Edith Gourdel (1 out of 3 patents)

14. Roman Lopez (1 out of 1 patent)

15. Frederic Colland (1 out of 1 patent)

10 patents: Sort by Forward Citations

1. 10478497 - Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer (2019-11-19),

2. 9546150 - Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 (2017-01-17),

3. 9328093 - Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications (2016-05-03),

4. 9315455 - Process for isomerizing fused bicyclic structures and preparation of vitamin D analogs comprising the same (2016-04-19),

5. 9314474 - Formulations of 14-epi-analogues of vitamin D (2016-04-19),

6. 8648076 - Cysteine protease inhibitors and their therapeutic applications (2014-02-11),

7. 8481514 - Therapeutical uses of inecalcitol (2013-07-09),

8. 7875613 - Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications (2011-01-25),

9. 7462615 - Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications (2008-12-09),

10. 6916615 - Collection of prokaryotic DNA for two hybrid systems Helicobacter pylori protein-protein interactions and application thereof (2005-07-12),

Hybrigenics is a biotechnology company that specializes in research, development, and commercialization of new therapeutic targets for cancers and orphan genetic diseases. The company uses its protein interaction mapping technology, ULTImate Y2H™, to identify novel drug targets for drug discovery and development. Hybrigenics also offers services for studying protein-protein interactions and drug screening.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

10 Patents

#330 in Paris

#1,665 in France

#54,238 in the World

Hybrigenics S.a.

Forward Citations = 41

29 inventors:

Rémi Delansorne (5 out of 5 patents)

Frédéric Colland (4 out of 4 patents)

Jean-Christophe Rain (4 out of 12 patents)

4. Philippe Guedat (3 out of 13 patents)

5. Etienne Formstecher (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…